ArticleDiabetic medicine : a journal of the British Diabetic Association2022
Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study.
Article in Diabetic medicine : a journal of the British Diabetic Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison.Advances in therapy · 2026Pooled it
- Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis.Systematic reviews · 2023Pooled it
- Tyrosine Kinase Receptors, Inhibition, and Potential Role in the Pharmacotherapy of Retinal Disorders.Ophthalmology and therapy · 2026Review
- Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema: 1-Year Results from the China RHINE Subpopulation.Ophthalmology and therapy · 2026Article
- Efficacy of brolucizumab and ranibizumab in diabetic macular edema and neovascular age-related macular degeneration: insights from a case series.Annals of medicine and surgery (2012) · 2026Article
- Early Latin American experience with faricimab for retinal diseases: FARI-LATAM study for the Pan-American collaborative retina study (PACORES) group.International journal of retina and vitreous · 2026Article
- Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.Eye (London, England) · 2025Article
- Predictive value of uninterrupted dry macula duration for discontinuation of anti-VEGF therapy in diabetic macular edema.Scientific reports · 2025Article
- Differentiating treatment episodes from gaps in eyes with diabetic macular oedema.The British journal of ophthalmology · 2025Article
- Does completion time of the initiation phase of anti-vascular growth factor affect visual and anatomical outcomes?: The MARMASIA study group report No.5.Eye (London, England) · 2025Article
- Planned vs. Performed Treatment Regimens in Diabetic Macular Edema: Real-World Evidence from the PACIFIC Study.Journal of clinical medicine · 2025Article
- Measures of diabetic retinopathy treatment coverage: protocol for a methodological review.BMJ open · 2025Article
- Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment.Pharmaceutics · 2025Article
- How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema.BMC ophthalmology · 2024Article
- An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective.Eye (London, England) · 2024Article
- Impact of COVID-19-related lifestyle changes on diabetic macular edema.International journal of ophthalmology · 2024Article
- Remote Monitoring of Visual Function in Patients with Maculopathy: The Aphelion Study.Ophthalmology and therapy · 2024Article
- Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1.Turkish journal of ophthalmology · 2023Article
- Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA.Ophthalmology and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnti-vascular endothelial growth factors (anti-VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study examined treatment patterns and outcomes in patients with DME treated with anti-VEGF therapy.
methodsUsing anonymized electronic medical record data collected from three UK sites, this retrospective cohort study assessed rates of anti-VEGF intravitreal injections in adults with treatment-naïve DME who received their first treatment between 1 September 2010 and 31 July 2018. The proportion of patients with at least one interval of at least 12 weeks between injections; the distribution of injection intervals; the discontinuation rates; and the number of anti-VEGF injection-, injection-free- and total visits were assessed during the first and second years of treatment.
resultsOverall, 1606 patient eyes with DME were included, with no minimum follow-up. During the first and second year of treatment, 63.2% and 73.1% of eyes had at least one anti-VEGF injection interval of at least 12 weeks, respectively. In the first and second years of treatment, the mean (standard deviation) numbers of injections were 7.7 (1.9) and 5.6 (2.2), with 14.2 (5.7) and 13.4 (6.4) total clinic visits, and 6.6 (5.0) and 7.8 (5.8) injection-free visits, respectively. In total, 27.8% of patient eyes discontinued treatment during the first 2 years.
conclusionsThe high number of clinic visits and high discontinuation rates demonstrate a significant unmet need for a treatment to enable sustainable extended injection intervals, while maintaining visual acuity. This could improve patient adherence and health-related quality of life for patients with DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.